In addition, the use of anti-TNF strategies is associated with increased risk of venous thromboembolic events [53], also more frequent in CKD patients [2], and clinical development was discontinued for several indications because of increased mortality or safety concerns [54]. This evidence concerns the gene TNF and chronic kidney disease.